Importance of basal fibroblast growth factor levels in patients with ovarian tumor
Authors:
V. Študent 1; C. Andrýs 2
; O. Souček 2
; J. Špaček 1; J. Tošner 1; I. Sedláková 1
Authors‘ workplace:
Porodnická a gynekologická klinika LF UK a FN, Hradec Králové, přednosta doc. MUDr. J. Špaček, Ph. D.
1; Ústav klinické imunologie a alergologie FN, Hradec Králové, přednosta prof. RNDr. J. Krejsek, CSc.
2
Published in:
Ceska Gynekol 2018; 83(3): 169-176
Overview
Objective:
Evaluation of importance of serum levels of basic fibroblast growth factor (bFGF) in patients with ovarian cancer, patients with border-line ovarian tumor, patients with benign ovarian cyst and women with normal ovarian tissue.
Design:
Prospective clinical study.
Setting:
Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove.
Methods:
Measurement of serum levels of bFGF by ELISA using reagents of company R&D Systems prior to treatment in a total of 74 consecutive coming women.
Results:
Serum level of bFGF from peripheral blood before treatment was significantly higher (p < 0.05) in patients with newly diagnosed ovarian cancer (n = 22), Med = 10.35 pg/ml (1.2–46.2 pg/ml) compared to patients with a border-line ovarian tumor (n = 9), Med = 5.4 pg/ml (1.6–6.8 pg/ml), patients with benign ovarian cyst (n = 24), Med = 5.2 pg/ml (0.1–67.2 pg/ml), and to women with normal ovarian tissue (n = 19) Med = 4.3 pg/ml (0.9–13.4 pg/ml). There isn‘t strong linear correlation (Spearman‘s rank correlation coefficient = 0.208791) between the serum level of bFGF and CA125 collected from peripheral blood before primary surgery or neoadjuvant chemotherapy in a group of patients with ovarian cancer (n = 14). We have not found significance correlation between age and serum levels of bFGF in patients with ovarian cancer, with border-line ovarian tumor, with benign ovarian cyst and in women with normal ovarian tissue.
Conclusion:
Serum levels of bFGF in patients with ovarian cancer are significantly higher than in patients with a border-line ovarian tumor, with benign ovarian cyst and in women with normal ovarian tissue regardless of age of patients.
Keywords:
ovarian cancer, basic fibroblast growth factor (bFGF), angiogenesis
Sources
1. Andrýs, C., Borská, L., Pohl, D., et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman’s therapy. Arch Dermatol Res, 2007, 298(10), p. 479–483.
2. Cibula, D., Petruželka, L., a kol. Onkogynekologie. 1. ed. Praha: Grada Publishing, 2009, 616 s.
3. Dušek, L., Mužík, J., Kubásek, M., et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2017-2-22]. Dostupný z http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.
4. Eskander, RN., Tewari, KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma – mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol., 2014, 132, p. 496–505.
5. Feng, QL., Shi, HR., Qiao, LJ., Zhao, J. Expression of hSef and FGF-2 in epithelial ovarian tumor. Zhonghua Zhong Liu Za Zhi, 2011, 33(10), p. 770–774.
6. Ferreras, C., Rushton, G., Cole, CL., et al. Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor. J Biol Chem, 2012, 287(43), p. 36132–36146.
7. Gacche, RN., Meshram, RJ. Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochim Biophysic Acta, 2014, 1846(1), p. 161–179.
8. Gao, F., Vasquez, SX., Su, F., et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol (Camb), 2011, 3(4), p. 479–489.
9. Gao, JM., Yan, J., Li, R., et al. Improvement in the quality of heterotopic allotransplanted mouse ovarian tissues with basic fibroblast growth factor and fibrin hydrogel. Hum Reprod, 2013, 28(10), p. 2784–2793.
10. Garor, R., Abir, R., Erman, A., et al. Effects of basic fibroblast growth factor on in vitro development of human ovarian primordial follicles. Fertil Steril, 2009, 91(5), p. 1967–1975.
11. He, B., Lin, J., Li, J., et al. Basic fibroblast growth factor suppresses meiosis and promotes mitosis of ovarian germ cells in embryonic chickens. General Comparative Endocrinol, 2012, 176(2), p. 173–181.
12. He, G., Holcroft, CA., Beauchamp, MC., et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Can, 2012, 34(6), p. 567–574.
13. Hillegass, JM., Shukla, A., MacPherson, MB., et al. Utilization of gene profiling and proteomics to determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1). J Toxicol Environ Health A, 2010, 73(5), p. 423–436.
14. Hsueh, SP., Hsu, WB., Wen, CC., et al. SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer. Cancer Gene Ther, 2011, 18, p. 859–870.
15. Kurman, RJ., Carcangiu, ML., Herrington, CS., Young, RH. WHO Classification of Tumours of Female Reproductive Organs. 4. ed. World Health Organisation, 2014, 6, 307 p.
16. Madsen, CV., Steffensen, KD., Olsen, DA., et al. Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors. Anticancer Res, 2012, 32(9), p. 3817–3825.
17. Parte, S., Bhartiya, D., Manjramkar, DD., et al. Stimulation of ovarian stem cells by follicle stimulating hormone and basic fibroblast growth factor during cortical tissue culture. J Ovarian Res, 2013, 6. DOI: 10.1186/1757-2215-6-20.
18. Prat, J., FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet, 2014, 124, 1, p. 1–5.
19. Robati, M., Ghaderi, A., Mehraban, M., et al. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts. Arch Gynecol Obstet, 2013, 288(4), p. 859–865.
20. Sadlecki, P., Walentowicz-Sadlecka, M., Szymanski, W., Grabiec, M. Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer. Ginekol Pol, 2011, 82(7), p. 498–502.
21. Saito, K., Khan, K., Sosnowski, B., et al. Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy. Laryngoscope, 2009, 119(4), p. 665–674.
22. Slaughter, KN., Thai, T., Penaroza, S., et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol, 2014, 133(1), p. 11–15.
23. Szubert, S., Szpurek, D., Moszynski, R., et al. Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. J Cancer Res Clin Oncol, 2014, 140(3), p. 361–369.
24. Wang, L., Ying, YF., Ouyang, YL., et al. VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model. J Assist Reprod Genet, 2013, 30(10), p. 1301–1311.
25. Watanabe, T., Shibata, M., Nishiyama, H., et al. Elevated serum levels of vascular endothelial growth factor is effective as a marker for malnutrition and inflammation in patients with ovarian cancer. Biomed Rep, 2013, 1(2), p. 197–201.
26. Watanabe, T., Shibata, M., Nishiyama, H., et al. Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer. Oncol Lett, 2014, 7(2), p. 373–377.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2018 Issue 3
Most read in this issue
- Prolactin and alteration of fertility
- Does EmbryoGlue transfer medium affect embryo transfer success rate?
- Vaccination against HPV and view of new possibilities
- Obesity and reduced fertility of men